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Abstract: Gentamicin is an aminoglycoside antibiotic commonly used for treating Pseudomo-
nas infections, but its use is limited by a relatively short half-life. In this investigation, devel-
oped a controlled-release gentamicin formulation using poly(lactide-co-glycolide) (PLGA) 
 nanoparticles. We demonstrate that entrapment of the hydrophilic drug into a hydrophobic PLGA 
polymer can be improved by increasing the pH of the formulation, reducing the hydrophilic-
ity of the drug and thus enhancing entrapment, achieving levels of up to 22.4 µg/mg PLGA. 
Under standard incubation conditions, these particles exhibited controlled release of gentamicin 
for up to 16 days. These particles were tested against both planktonic and biofilm cultures of 
P. aeruginosa PA01 in vitro, as well as in a 96-hour peritoneal murine infection model. In this 
model, the particles elicited significantly improved antimicrobial effects as determined by 
lower plasma and peritoneal lavage colony-forming units and corresponding reductions of the 
surrogate inflammatory indicators interleukin-6 and myeloperoxidase compared to free drug 
administration by 96 hours. These data highlight that the controlled release of gentamicin may 
be applicable for treating Pseudomonas infections.
Keywords: anti-microbial, gentamicin, PLGA nanoparticles, Pseudomonas aeruginosa
Introduction
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogenic bacterium 
which is naturally present in water, soil, and vegetation.1 P. aeruginosa colonization 
and subsequent infection can occur in patients through a number of mechanisms such as 
trauma, surgery, a major wound, or the presence of an in-dwelling device.2–4 The bac-
terium can also colonize through disruption of the normal flora balance due to admin-
istration of a broad-spectrum antibiotic or dysfunction of the immune system.5
P. aeruginosa is one of the most common pathogens in nosocomial and 
 ventilator-associated pneumonia, urinary tract infections, burn wounds, and blood 
stream infections.6,7 In addition to acute infection, P. aeruginosa is responsible for 
debilitating chronic lung infection in immunocompromised patients, cystic fibrosis 
sufferers, and individuals receiving chemotherapy.8,9
One of the most widely used antibiotics for treating pseudomonal infections is 
gentamicin. Gentamicin is an aminoglycoside that binds to the 30S ribosomal subunit 
of bacterial cells, inhibiting protein synthesis.10 However, this antibiotic, similarly 
to other aminoglycosides, has a relatively short half-life, low bioavailability, and 
may cause side effects such as ototoxicity and nephrotoxicity.11 Therefore, formu-
lation approaches to control its release may have clinical usefulness. Gentamicin 
have been previously examined in a wide variety of nanoparticle delivery systems, 
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including poly(lactide-co-glycolide) (PLGA), chitosan, and 
caroboxymethyldextran-b-poly(ethyleneglycols).12–14
The application of antibiotic nanoparticle formulations 
has been shown to offer several advantages over conven-
tional administration and delivery methods, including the 
ability for drug delivery to a specific site such as an intra-
cellular infection.15,16 Nanoparticles can also be exploited 
to facilitate sustained release of an antibiotic, minimizing 
dosing  regimens.17 Furthermore, nanoparticles can mask 
the entrapped drug, reducing systemic toxicity induced by 
conventional administration of the free drug.18 Moreover, 
polymeric nanoparticles have shown to enhance the oral 
bioavailability of orally inactive antibiotics.13
PLGA polymers have been used to entrap several antibi-
otics in nanoparticle formulations, demonstrating improved 
delivery and antibiotic efficacy.19–21 Although encapsulation 
and the biological usefulness of gentamicin in PLGA have 
been previously reported, encapsulation efficiencies have 
been modest. With higher drug encapsulation, it is possible 
that further improved biological effects can be determined.12 
Therefore, in this study we developed an approach to increase 
gentamicin entrapment in PLGA nanoparticles. We exam-
ined the efficacy of these controlled release particles in vitro 
and in vivo against P. aeruginosa infection, highlighting 
improved biological outcomes over administration of the 
nonencapsulated drug.
Materials and methods
Materials
PLGA (50/50) Resomer 502H (molecular weight 12 kDa) was 
purchased from Boehringer Ingelheim (Ingelheim am Rhein, 
Germany). Polyvinyl alcohol (PVA) and gentamicin sulfate 
was purchased from Sigma-Aldrich (Dorset, UK). Acetone 
and dichloromethane were purchased from VWR (Lutterworth, 
Leicestershire, UK). Water was double- distilled and of HPLC 
grade. P. aeruginosa PA01 was stored at −70°C in Microbank 
vials (Pro-Lab Diagnostics, Cheshire, UK), and was subcul-
tured in Luria Bertani (LB) broth and agar prior to use.
Preparation of PLGA nanoparticles
Two methods for preparing nanoparticles were employed. 
For water-in-oil-in-water (w/o/w) formulations, the emulsion 
evaporation was prepared by dissolving 3.5 mg of gentamicin 
in 0.5 mL of water, and this mixture was emulsified with 
2 mL of dichloromethane containing 100 mg of PLGA by 
sonication at 20 mV. The primary w/o emulsion was emul-
sified with 10 mL of aqueous PVA (2.5% in 25 mM MES 
buffer) at different pH adjustments (pH 5 and 7.4).
For solid-in-oil-in-water (s/o/w) formulations, 3.5 mg 
gentamicin was dissolved in 0.1 mL of water. The gentami-
cin solution was then added to 2 mL of acetone containing 
100 mg PLGA. The diffusion of water into the acetone 
results in the formation of solid gentamicin nanoparticles. 
The s/o phase was then added to 10 mL of PVA (2.5% in 
25 mM MES buffer) buffer at different pH adjustments 
(pH 5 and 7.4). The diffusion of the acetone phase into the 
aqueous PVA phase resulted in the coating of the gentamicin 
with PLGA and thus the formation of gentamicin-loaded 
PLGA nanoparticles. The proportion of gentamicin entrapped 
was determined by derivatization using orthophthaldehyde 
as described previously.22
Nanoparticle characterization
The particle size, polydispersity index (PI), and zeta potential 
of the nanoparticles was measured using photon correlation 
spectroscopy (3000 HS; Malvern Instruments, Malvern, 
UK). Measurements were carried out using a monochromatic 
coherent He-Ne laser light of a fixed wavelength (633 nm) 
at 90° and at room temperature (25°C), with each sizing 
determination conducted in triplicate; the average particle 
size is expressed as the mean diameter (Z
ave
).
In vitro release of gentamicin  
from PLGA nanoparticles
The release of gentamicin was measured by incubating 
1 mL of nanoparticles at 10 mg/mL PLGA in phosphate-
buffered saline (PBS) (pH 7.4) at 37°C using a dialysis cell 
with a 10,000 Da cut-off membrane. At each time point, the 
receiver compartment was collected and replaced with fresh 
PBS. The sampled receiver was diluted 1:2 with 0.4 M boric 
acid pH 9.7 before derivatization with orthophthaldehyde as 
before. Fluorescence was measured at a λ
ex
/λ
em
 of 360/460, 
respectively, and compared to a calibration curve of gen-
tamicin in 0.4 M boric acid pH 9.7. The average cumulative 
release was then plotted for three different preparations of 
each formulation.
Planktonic and biofilm susceptibility assays
Pseudomonas aeruginosa (PA01) was grown in LB broth for 
18–24 hours at 37°C. Actively growing inoculum was diluted 
to an optical density of 0.3 (A
550
) and then further diluted 
to give a starting inoculum of 2 × 105 colony-forming units 
(CFU)/mL. Diluted PA01 (150 µL) was added to each well 
of a sterile 96-well plate. The minimum inhibitory concen-
tration (MIC) was determined for planktonic PA01 chal-
lenged with either gentamicin or nanoparticle formulations. 
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The lowest concentration of challenge at which no observable 
growth was apparent after 24 hours was designated as the 
MIC. The minimum bactericidal concentration (MBC) was 
determined by the absence of growth on LB agar plates from 
20 µL samples from challenged wells after 24 hours.
Biofilm susceptibility assays were performed using 
the MBEC Assay for Physiology and Genetics (P&G) 
 (Innovotech, Edmonton, Alberta, Canada). Diluted PA01 
(150 µL, 2 × 105 CFU/mL) was added to each well of an 
MBEC plate and incubated for 24 hours at 37°C in a gyro-
rotary incubator to allow biofilm formation on the pegs of 
the MBEC plate lid. Biofilms pegs were immersed twice for 
2 minutes in sterile 0.9% NaCl (200 µL per well) to remove 
loosely adhered bacteria, after which they were challenged 
with a range of concentrations of either free gentamicin 
or nanoparticle formulations (0–100 µg/mL) in 200 µL 
media (5 replicates per condition) for 24 hours at 37°C in a 
gyrorotary incubator. After challenge, pegs were rinsed as 
described above and then placed in a recovery plate consist-
ing of 200 µL of LB broth per well. Biofilms were disrupted 
by ultrasonic treatment for 10 minutes, and then grown for 
24 hours at 37°C. The lowest concentration of challenge at 
which no observable growth was apparent after 24 hours 
was designated as the minimum biofilm eradication con-
centration (MBEC).
In vitro dialysis clearance model
MBEC plates were used to grow mature biofilms as described 
above. Biofilms were challenged with both free and nano-
particle encapsulated gentamicin in continuous exchange 
 dialysis cells. Pegs with adhered biofilms were placed in 
dialysis cells in the receptor compartment containing 9 mL 
LB. Next, 1 mL of PBS, free gentamicin (0.8 mg/mL), or 
gentamicin PLGA nanoparticle formulations (0.8 mg/mL) 
was added to the donor compartment and incubated for 
36 hours, during which time half the dialysis reservoir vol-
ume was replaced with fresh media every 60 minutes. After 
incubation, the pegs were sonicated to liberate bacteria and 
plated to allow enumeration of viable CFUs as before.
Comparison of efficacy of free versus 
nanoparticle-formulated gentamicin in vivo
Pseudomonas aeruginosa (PA01) was grown overnight in 
nutrient agar at 37°C with constant agitation. The bacteria 
were centrifuged at 2000 × g and washed 3 times in sterile 
PBS. The bacteria were resuspended in sterile injection-
grade saline and the concentration adjusted to an optical 
density of 1 (A
550
). A further 1 in 10 dilution resulted in a 
 suspension of approximately 107 CFU/mL. Female, 12-week-
old CD-1 mice were infected intraperitoneally with 100 µL 
of the bacterial suspension and subsequent growth of the 
inoculum on nutrient agar demonstrated that each mouse 
received 6 × 106 CFU. After 8 hours, the mice were treated 
with 0.4 mg/kg of either free gentamicin (n = 15), gentamicin 
nanoparticles (n = 15), or a saline control (n = 15) by intra-
peritoneal injection. The mice were regularly weighed and 
monitored throughout the course of infection; any animal 
reaching a predetermined humane end-point (15% loss of 
body weight, loss of response to tactile stimuli, or loss of 
righting response) was culled. At predetermined time points 
(24, 48, and 96 hours postinfection), animals were culled by 
lethal injection with rompun/ketamine. Blood was collected 
by cardiac puncture and placed into a tube containing 100 U 
of preservative-free sodium heparin. Peritoneal lavage was 
carried out with 1 mL of cold sterile PBS, and the volume 
of fluid recovered was recorded. The spleen was removed 
and weighed. Serial dilutions of blood and lavage fluid 
were plated onto nutrient agar, while the remaining blood 
and lavage fluid was centrifuged at 800 × g and the plasma/
supernatant were carefully removed and stored at −80°C 
until use. Bacterial colonies were counted after 24 hours of 
growth at 37°C.
Quantification of inflammatory mediators
Interleukin (IL)-6 was quantified in the mouse plasma and 
peritoneal lavage fluid using an enzyme-linked immunosor-
bent assay (ELISA) following the manufacturer’s protocol 
(R&D Systems, Minneapolis, MN, USA). Briefly, 96-well 
plates were coated with an IL-6-specific capture antibody and 
incubated at 4°C for 18 hours. To reduce nonspecific bind-
ing, the plate was blocked with 1% bovine serum albumin 
at room temperature for 1 hour. The plate was washed with 
PBS containing 0.5% Tween-20 (v/v), and the samples and 
known concentrations of recombinant cytokine were applied 
to the plate. The plate was incubated at room temperature 
for 1 hour, washed, and a secondary horseradish peroxidase-
conjugated anti-IL-6 antibody was applied. After incubation 
for 1 hour followed by washing, One-Step TMB Substrate 
(Thermo Scientific, Rockford, IL) was applied; and after 
20 minutes, the reaction was stopped with sulfuric acid and 
optical densities were measured (A
450
). A standard curve was 
used to calculate the amount of IL-6 in the samples.
Myeloperoxidase (MPO) activities were assayed from peri-
toneal lavage fluid (50 µL) or known concentrations of MPO 
purified from human leukocytes (Sigma-Aldrich) applied to a 
black 96-well plate (Thermo Scientific). Assay reagent (50 µL), 
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consisting of 50 µM Ampliflu Red (Sigma -Aldrich) and 20 µM 
hydrogen peroxide (Sigma-Aldrich) in 0.1 M potassium phosphate 
dibasic solution (Sigma-Aldrich), was then applied. The plate 
was incubated for 30 minutes at room temperature in the dark. 
Fluorescence was measured at λ
ex
/λ
em
 of 530/590.
Statistical analysis
Statistical analysis was performed using Student’s t-test 
to compare all pairs of preparations (GraphPad Prism, San 
Diego, CA). For in vivo studies, weight loss values were 
normalized using an arcsine transformation. A spleen-to-
body weight ratio was calculated, and the ratio was normal-
ized using a square root calculation. Statistical analysis was 
performed using Student’s t-test to compare all pairs of 
preparations. Rejection of the null hypothesis was considered 
when the P value was ,0.05. Results are presented as the 
mean ± SEM unless stated otherwise.
Results
Encapsulation of gentamicin  
in PLGA nanoparticles
We examined the anti-microbial effect of sustained-release 
gentamicin from PLGA nanoparticles towards P. aeruginosa 
using two methodologies for generating drug-entrapped 
formulations. These included water-in-oil-in-water (w/o/w) 
and solid-in-oil-in-water (s/o/w) fabrication approaches. 
Using a standard w/o/w approach, we generated particles in 
a range of 251 nm, encapsulating up to 6.4 µg of drug per 
mg PLGA (Table 1). This is similar to the results of previ-
ously published studies entrapping gentamicin in PLGA.12 
To examine the effects of the charge of both the polymer and 
the drug during the formulation process, we then altered the 
pH of the aqueous phase from 5.0 to 7.4 and observed an 
approximate threefold increase in drug entrapment in PLGA 
nanoparticles (22.4 µg per mg PLGA, Table 1) without sig-
nificant alterations to the particle diameter and zeta potential. 
Similarly, using an s/o/w fabrication approach, an increase 
in entrapment of gentamicin from 7.3 µg per mg PLGA to 
21 µg per mg PLGA was observed when pH was increased 
from 5 to 7.4 (Table 1). However, the size and polydispersity 
of the preparations using the s/o/w methodology were higher. 
For example, s/o/w particles formulated at pH 7.4 had a 
diameter of 359 nm with a polydispersity of 0.23 compared 
to 241 nm and 0.12 for w/o/w formulations prepared at pH 
7.4. This is a likely consequence of the lack of the sonica-
tion step in the s/o/w procedure, which has previously been 
observed to decrease diameter and improve polydispersity 
of PLGA nanoparticles.23
We next analyzed gentamicin release from both the w/o/w 
and s/o/w particles and observed a typical biphasic release 
profile with nearly 50% released after 24 hours, but with 
continued release over at least 16 days for both formulations 
prepared at pH 7.4 (Figure 1A). A similar sustained release 
profile was observed for both nanoparticle formulation strate-
gies prepared at pH 5 (Figure 1B). However, the preparations 
formulated at pH 5 displayed a slower initial burst release 
phase, with only approximately 25% released within the first 
24 hours. However, by day 7, cumulative releases were simi-
lar to those of particles prepared at pH 7.4, and it is possible 
that the initial release variations may be due to differences 
in drug distribution in the corona and core of the particles 
formulated under different pH conditions.
Antimicrobial activity of gentamicin-PLGA 
nanoparticles
To ensure the functionality of the drug formulation, the abil-
ity to inhibit growth of P. aeruginosa (PA01) in planktonic 
cultures was determined. Culture growth after 24 hours was 
measured following incubation with varying concentrations 
of free gentamicin and nanoparticle-entrapped gentamicin 
(both w/o/w and s/o/w formulations) (Figure 1C). It was 
clearly observed that the free gentamicin was able to inhibit 
bacterial growth (MIC of 1.5 µg/mL). Both the w/o/w and 
s/o/w formulations inhibited growth, albeit with less effec-
tiveness than the free drug (MIC of 3.0 µg/mL for both prepa-
rations) (Table 2). The control blank nanoparticles exhibited 
Table 1 Formulation of gentamicin nanoparticles using w/o/w and s/o/w approaches
Formulation Particle size  
(nm)
PI Zeta potential  
(mV)
Drug entrapment  
(μg per mg PLGA)
w/o/w ph 5 251.6 ± 7.5 0.10 ± 0.02 1.5 ± 0. 4 6.4 ± 1.1
w/o/w ph 7.4 241.3 ± 12.4 0.12 ± 0.04 0.7 ± 0.2 22.4 ± 2.5
s/o/w ph 5 302.4 ± 19.1 0.29 ± 0.09 2.3 ± 1.1 7.3 ± 2.3
s/o/w ph 7.4 358.5 ± 22.9 0.23 ± 0.02 −0.4 ± 1.1 21.0 ± 5.1
Notes: Results are presented as mean ± SD, n = 3.
Abbreviations: PI, polydispersity index; s/o/w, solid-in-water-in-oil formulation; w/o/w, water-in-oil-in-water formulation.
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Figure 1 Characterization of gentamicin PLGA nanoparticle formulations. Percentage release profiles of drug from nanoparticles were analyzed at 37°C for both water-in-
oil-in-water (w/o/w) and solid-in-water-in-oil (s/o/w) formulation approaches for nanoparticles prepared at ph 7.4 (A) and ph 5 (B). Graphs show cumulative percentage 
release (mean ± SD, n = 3). (C) Analysis of w/o/w and s/o/w formulations to inhibit growth of planktonic P. aeruginosa PA01 cultures as determined by measurement of 
absorbance at 550 nm (mean ± SD, n = 5). (D) Evaluation of gentamicin nanoparticles towards P. aeruginosa biofilms. Preformed biofilms were prepared on MBEC pegs prior 
to incubation with either gentamicin or w/o/w formulated gentamicin nanoparticles for 24 hours. Recovered residual bacteria were then cultured overnight and culture 
growth was measured at 550 nm (mean ± SD, n = 5).
Abbreviations: MBEC, minimum biofilm eradication concentration; NP, nanoparticle; s/o/w, solid-in-water-in-oil formulation; w/o/w, water-in-oil-in-water formulation.
Table 2 MIC, MBC, and MBEC values for gentamicin formulations
MIC  
(μg/mL)
MBC  
(μg/mL)
MBEC 
(μg/mL)
Free unentrapped gentamicin 1.5 3.0 50
Gentamicin-loaded w/o/w 
formulation
3.0 6.0 100
Gentamicin-loaded s/o/w  
formulation
3.0 6.0 N/A
Abbreviations: MBC, minimum bactericidal concentration; MBEC, minimum 
biofilm eradication concentration; MIC, minimum inhibitory concentration; s/o/w, 
solid-in-oil-in-water formulation; w/o/w, water-in-oil-in-water formulation.
no significant inhibition of bacterial growth, highlighting 
that the antimicrobial effects were elicited by the drug itself. 
In addition to analyzing bacterial growth inhibition, we also 
analyzed the bactericidal effect of the formulations observing 
an MBC of free drug at 3.0 µg/mL compared to 6.0 µg/mL 
for the w/o/w and s/o/w formulations (Table 2).
Although both formulations had similar anti-microbial 
effects, the w/o/w particles had a smaller polydispersity, 
making them more uniform, which was preferable for down-
stream studies to control for possible variables such as release 
and biodistribution. Therefore, only the w/o/w preparation 
prepared at pH 7.4 was subsequently investigated.
Effect of gentamicin PLGA nanoparticles 
on P. aeruginosa biofilms
Pre-formed P. aeruginosa (PA01) biofilms on polystyrene 
pegs were grown using the Calgary Biofilm device as pre-
viously described and were challenged with both free drug 
and drug-loaded nanoparticles for 24 hours.25 As shown in 
Figure 1D and Table 2, MBEC concentrations were similarly 
affected by encapsulation of the drug into the nanoparticles 
where the w/o/w formulation MBEC was determined as 
100 µg/mL as opposed to the free drug at 50 µg/mL (Table 2). 
The much higher MBEC values (relative to MIC and MBC) 
observed for both free and encapsulated drug are likely due 
to the interaction of the anionic mucopolysaccharide in the 
biofilm with the cationic aminoglycoside, limiting the amount 
of free drug available to act against the resident bacteria.24
The ability of the particles to provide controlled antibiotic 
release and enhance antimicrobial effects against biofilms in 
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a continuous exchange dialysis method to mimic the in vivo 
lung half-life of gentamicin was next examined. A preformed 
PEG biofilm was placed in a receiver compartment and drug 
treatments were added to the reservoir compartment (Fig-
ure 2A). Preformed biofilm on pegs were challenged with 
both free and nanoparticle-encapsulated gentamicin in this 
clearance model system in which half the dialysis reservoir 
volume was replaced with fresh media every 60 minutes to 
mimic typical lung clearance of free gentamicin.26,27 After 
incubation for 36 hours in continuous exchange dialysis cells, 
the treated pegs were examined for antimicrobial effects. 
Although free gentamicin showed activity towards biofilm 
bacteria, entrapment and release from PLGA nanoparticles 
significantly enhanced this effect (Figure 2B). Thus, continu-
ous exposure of the biofilm to the antibiotic through sustained 
release from nanoparticles improved efficacy over a single 
dosage of free drug.
Treatment of systemic P. aeruginosa 
infection with gentamicin-loaded 
nanoparticles
Using an in vivo murine peritoneal infection model, we next 
evaluated the potential of the optimized formulation to chal-
lenge infection in mice. The 12-week-old CD-1 mice were 
infected intraperitoneally with a PA01 inoculum and treated 
after 8 hours with 0.4 mg/kg of free gentamicin, gentamicin 
PLGA nanoparticles, or a saline control. After 96 hours, 35% 
of the control saline-treated group had died. In both drug 
treatment arms, an identical increase in survival (15% mortal-
ity) was observed over this timeframe (data not shown).
No significant difference was observed in baseline weight 
of mice in all groups prior to infection with PA01. During 
the study, weight measurements were taken regularly; at 
48 hours, weight loss was significantly reduced only in the 
group treated with the gentamicin nanoparticle formula-
tion (P = 0.045) (Figure 3A). The spleen: total body weight 
ratio was also examined, and it was found that the ratio was 
significantly smaller in the gentamicin nanoparticle treated 
cohort compared to the control and free gentamicin drug 
treatment groups at 48 hours (P = 0.03) (Figure 3B). No 
significant differences were observed at other time points 
(data not shown).
Peritoneal lavage fluid samples were taken from infected 
mice at 24-, 48-, and 96-hour time points and CFU from 
each sample was compared. As shown in Figure 4A, at 
24 hours there was no distinguishable differences in CFU 
recovered from peritoneal lavage from any treatment groups, 
but there was a small reduction in CFU recovered from the 
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Figure 2 (A) Schematic presentation of the in vitro dialysis model for lung. The nanoparticles were placed in a dialysis membrane with a 10,000 Da cut-off (reservoir 
compartment) to allow free gentamicin but not nanoparticles to pass through. half of the receiver compartment liquid was taken every hour and replaced with free LB 
media as indicated by the red and the green arrows. (B) Gentamicin-loaded nanoparticles showed improved activity towards biofilms in a continuous exchange dialysis cell 
as shown by the lower number of colony-forming units. Pegs with pre-formed biofilms were placed in dialysis cells with either free gentamicin or nanoparticle formulations 
and incubated for 36 hours, during which time half the dialysis reservoir volume was replaced each hour with fresh media. 
Notes: ***P , 0.005; mean ± SD, n = 5.
Abbreviations: LB, Luria Bertani broth; NP, nanoparticles.
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Figure 4 (A) Bacterial counts (CFU/mL) in BAL fluid of mice treated with gentamicin nanoparticles, free gentamicin, and normal saline at 24, 48, and 96 hours. (B) Bacterial 
counts (CFU/mL) in plasma of mice treated with gentamicin nanoparticles, free gentamicin, and normal saline at 24, 48, and 96 hours. 
Notes: *P , 0.05; n = 4.
serum of animals treated with gentamicin in either its free or 
 nanoparticle-encapsulated form (Figure 4B). After 48 hours, 
it was clear that both free and nanoparticle-encapsulated gen-
tamicin had effectively cleared the infection in both the lavage 
and serum, but by 96 hours the effectiveness of free gentami-
cin was ablated and the bacteria population had expanded to 
levels comparable with animals dosed with saline control. 
Conversely, the gentamicin nanoparticles were still effective 
in significantly reducing CFU/mL from the peritoneal lavage 
(P = 0.015) at this time point (Figure 4A).
In addition to sampling of the peritoneal lavage, blood 
samples from the animals were also plated to measure CFU as a 
result of the treatment so that sentence reads simply ‘at the same 
time intervals.’ the same time intervals. After 24 and 48 hours, 
treatment of infected animals with either free gentamicin or 
gentamicin-loaded particles resulted in a nonsignificant reduction 
of CFU per mL of blood (Figure 4B). However, as observed in the 
peritoneal lavage fluid, at 96 hours postinfection, nanoparticle-
treated animals showed a significant reduction in bacterial CFU 
compared to nontreated controls (P = 0.03) (Figure 4B).
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4059
Gentamicin nanoparticles inhibit Pseudomonas infection
International Journal of Nanomedicine 2012:7
Correspondingly, MPO levels in the lavage fluid, an 
indicator of neutrophil infiltration at the infection site, 
were also reduced in mice treated with gentamicin-loaded 
nanoparticles compared to free drug at 96 hours (P = 0.014) 
(Figure 5). Finally, the inflammatory mediator IL-6, which is 
used as a surrogate marker of disease severity, was signifi-
cantly reduced in the peritoneal lavage fluid of nanoparticle-
treated animals compared to nontreated controls (P = 0.03) 
(Figure 6A). Similar trends were also observed for serum 
IL-6 levels (Figure 6B). These data agree with the results 
of in vitro analysis demonstrating that controlled release 
from nanoparticles elicits improved antimicrobial effects 
in vivo towards P. aeruginosa infection compared to the 
free drug, which was effectively cleared from the animals 
by this time.
Discussion
In the current study, we developed an improved formulation 
of the aminoglycoside antibiotic gentamicin into PLGA 
nanoparticles and investigated its application towards 
P. aeruginosa in planktonic cultures, biofilms, and an in vivo 
model of systemic infection. Our results show that the PLGA 
formulation of gentamicin has improved antimicrobial effects 
towards peritoneal infection of P. aeruginosa in vivo.
The preparation of gentamicin-encapsulated PLGA 
particles has been examined previously and was shown to 
aid in drug delivery to latent intracellular infection, as in the 
case of Brucella melitensis.12 PLGA is a clinically approved, 
biodegradable, and biocompatible polymer considered safe 
for controlled release formulations.28 However, a potential 
limiting factor in the preparation of gentamicin-containing 
PLGA nanoparticles is the hydrophobic nature of the poly-
mer in contrast to the hydrophilic characteristics of the drug. 
 Generally, entrapment of hydrophobic drug molecules in 
PLGA preparations is preferred, a consequence of favorable 
hydrophobic interactions between the polymer and drug 
during formulation. Given the high water solubility of gen-
tamicin (50 mg/mL), it is not surprising that previous reports 
investigating its entrapment in PLGA nanoparticles have 
reported modest values of 6–10 µg/mg PLGA.12 Several tech-
niques have been designed to entrap hydrophilic drugs into 
PLGA nanoparticles. One of the most widely used techniques 
is the w/o/w emulsion evaporation method.29 This technique 
is based on providing an aqueous core containing the drug, 
which is coated by a polymer shell. Alternatively, the s/o/w 
procedure has also been proposed, predominantly for hydro-
philic proteins.30 Using these approaches, drug entrapment 
levels observed in this study broadly agreed with the results 
of previous studies.12 However, to increase entrapment 
efficiency, we examined the effect of altering the pH of the 
external aqueous phase. This approach has previously been 
used to improve entrapment of other drug entities in PLGA 
such as vincristine sulfate.31 Gentamicin has four amino 
 moieties with pK
a
 values of approximately 8.6; we hypoth-
esized that increasing the pH of the aqueous phase would 
favor deprotonation of these groups (NH
3
+ to NH
2
) and render 
the drug molecule less hydrophilic, making it amenable to 
encapsulation in PLGA.32 This strategy proved successful, 
with a pH shift of the aqueous external phase from 5 to 7.4 
resulting in a threefold increase in entrapment efficiency in 
both formulation strategies.
Subsequent analysis of drug release from these particles 
demonstrated typical biphasic release profiles over at least 
16 days with no tangible differences in release observed 
between the various formulations. We then examined 
the application of the particles, using them to challenge 
both planktonic P. aeruginosa (PA01) and preformed 
biofilm in vitro, showing that gentamicin encapsulated in 
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 nanoparticles retained its anti-bacterial activity on planktonic 
and biofilm cultures.
It has been previously demonstrated that  gentamicin 
exhibits time-dependent bactericidal activity.33 To 
 examine whether the time dependent killing is superior to 
a single high dose for in the short-term on PA01 biofilm, 
we designed a rapid drug clearance model of the in vivo 
process using a dialysis chamber system. We showed 
that challenging a mature biofilm with a sustained release 
of gentamicin from nanoparticles resulted in a signifi-
cant reduction in P. aeruginosa CFU compared to free 
 gentamicin. This finding suggests that controlled release 
of gentamicin nanoparticles may have increased efficacy 
over free gentamicin in vivo.
We then explored the application of gentamicin par-
ticles in vivo to clear systemic P. aeruginosa infection in 
mice, highlighting that although a dose of free drug was 
able to reduce infection after 24 hours, bacterial levels had 
returned to levels comparable to the saline-treated controls 
by 96 hours. However, when the animals were treated with 
an equal concentration of nanoparticle-entrapped drug, this 
protective effect was still observed after 96 hours. These 
findings were re-enforced by complementary reductions in 
the levels of the pro-inflammatory cytokine IL-6, decreased 
MPO activity, a surrogate marker of neutrophil activation, 
and reduced splenic enlargement. Collectively, this data 
clearly shows that PLGA nanoparticles loaded with gen-
tamicin have improved activity over free gentamicin. The 
sustained release of antibiotic provided longer antimicrobial 
effectiveness towards P. aeruginosa infection.
It may be possible to improve the efficacy of these 
nanoparticles by increasing their bioavailability. Here, the 
particles were delivered intraperitoneally, and it is well 
established that uncoated PLGA nanoparticles are readily 
opsonized by macrophages,34 and therefore it is likely that 
a large proportion of the nanoparticles delivered in vivo 
were endocytosed by immune cells. A recent study examin-
ing the biodistribution of orally administered fluorescently 
labeled PLGA nanoparticles showed that they could remain 
in circulation for several days, with most accumulating in 
the liver and kidney, causing no obvious toxicity.35 Despite 
this, it is also known that modification of the nanoparticle 
surface with a hydrophilic corona using a polymer such as 
polyethylene glycol can reduce opsonization, increasing 
circulation times and minimizing normal tissue exposure to 
cargo drugs.34 It would be interesting to determine whether 
such surface modifications of the particles alters the distribu-
tion of gentamicin and its therapeutic effect.
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Conclusion
In summary, we enhanced the in vitro and in vivo antimicro-
bial effects of gentamicin on planktonic- and biofilm-based 
infections through optimized encapsulation and controlled 
release from PLGA nanoparticles. Gentamicin is considered a 
valuable drug for treating sepsis and Pseudomonas infections, 
but the high dosages required can induce ototoxicity and neph-
rotoxicity.36,37 Therefore, controlled release of gentamicin may 
decrease undesirable side effects.  Furthermore, nanoparticle 
and microparticle preparations have the potential to be used in 
aerosol delivery and may enhance the therapeutic effectiveness 
and dose control of this and other aminoglycosides for treating 
pulmonary infections.
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